Chromocell Therapeutics Azioni (AMEX: CHRO)

Ultime notizie per Chromocell Therapeutics (AMEX:CHRO) Azioni

Chromocell Therapeutics

Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.

Chromocell Therapeutics Corporation Common Stock

Chromocell Therapeutics Corp

CHROMOCURE INC by Chromocure, Inc.

ChromaDex Corp

Chromia - United States Dollar

Chronicle

Chrono.tech - United States Dollar

Citigroup analyst Patrick Donnelly maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Buy and raises the price target from $155 to $190.

News

Price Target

Analyst Ratings

ILMN

Citigroup Maintains Buy on Illumina, Raises Price Target to $190

Needham analyst Mike Cikos reiterates DigitalOcean Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) with a Hold.

Reiteration

DOCN

Needham Reiterates Hold on DigitalOcean Holdings

Citigroup analyst Daniel Grosslight maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Buy and lowers the price target from $21 to $18.5.

Citigroup Maintains Buy on Owens & Minor, Lowers Price Target to $18.5

Deutsche Bank analyst Benjamin Black maintains Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Buy and lowers the price target from $18 to $16.

WBTN

Deutsche Bank Maintains Buy on Webtoon Entertainment, Lowers Price Target to $16

Deutsche Bank analyst Benjamin Soff maintains New York Times (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>) with a Buy and raises the price target from $65 to $66.

Deutsche Bank Maintains Buy on New York Times, Raises Price Target to $66

Deutsche Bank analyst Ross Seymore maintains Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) with a Buy and lowers the price target from $6 to $4.

NVTS

Deutsche Bank Maintains Buy on Navitas Semiconductor, Lowers Price Target to $4

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $14 price target.

BCRX

Needham Reiterates Buy on BioCryst Pharma, Maintains $14 Price Target

Citigroup analyst Jason Bazinet maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Buy and raises the price target from $53 to $63.

RBLX

Citigroup Maintains Buy on Roblox, Raises Price Target to $63

Biotech

General

MAIA

MAIA Biotechnology To Present Late-Breaking THIO-101 Phase 2 Trial Updates On THIO And Cemiplimab Combo In NSCLC At SITC 2024, Highlighting Long-Term Therapeutic Benefits Beyond Treatment Cessation

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Neutral and raises the price target from $204 to $206.

KRYS

Citigroup Maintains Neutral on Krystal Biotech, Raises Price Target to $206

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.22% to 41,887.70 while the NASDAQ rose 0.70% to 18,307.76. The S&amp;P 500 also rose, gaining, 0.50% to 5,741.41.
Check This Out: <a href="https://www.benzinga.com/news/24/11/41741538/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Information technology shares rose by 0.9% on Tuesday.
In trading on Tuesday, health care shares fell by 0.3%.
Top Headline
The trade deficit in the U.S. increased to $84.4 billion in September, recording the highest level since April 2022, and above market estimates of a $84.1 billion gap, versus a revised $70.8 billion gap in August.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Bionomics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares shot up 190% to $0.5583 after the company announced it secured an AUS$1 million milestone payment from Carina Biotech for its BNC101 oncology program, with the potential to earn up to AUS$118 million.</li>
<li>Shares of Avalon GloboCare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>) got a boost, surging 68% to $3.78.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares were also up, gaining 60% to $2.92 after the company highlighted data showing the potential of inflammasome inhibition to protect pancreatic islet beta cells and attenuate progression from obesity to insulin resistance and type 2 diabetes.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) shares dropped 36% to $3.79 after the company reported worse-than-expected Q3 sales results. Also, multiple firms downgraded their respective ratings on the company and lowered their respective price targets.</li>
<li>Shares of Verrica Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) were down 36% to $0.91 following downbeat quarterly results.</li>
<li>Bioventus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) was down, falling 36% to $8.77 after the company announced third-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $71.92 while gold traded up 0.3% at $2,754.40.
Silver traded up 0.8% to $32.880 on Tuesday, while copper rose 1.1% to $4.4795.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.1%, Germany's DAX gained 0.2% and France's CAC 40 rose 0.2%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 fell 0.2%.
Spain's consumer confidence indicator declined by 4.6 points to a reading of 84.8 in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 1.11%, Hong Kong's Hang Seng Index gaining 2.14%, China's Shanghai Composite Index gaining 2.32% and India's BSE Sensex gaining 0.88%.
Economics
The trade deficit in the U.S. increased to $84.4 billion in September, recording the highest level since April 2022, and above market estimates of a $84.1 billion gap, versus a revised $70.8 billion gap in August.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41743859/top-3-consumer-stocks-that-may-keep-you-up-at-night-this-quarter">Top 3 Consumer Stocks That May Keep You Up At Night This Quarter</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Markets

ALBT

BNOX

VRCA

ZVSA

Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September

Trading Ideas

ZCAR

Zoomcar Holdings Shares Halted To The Upside; Stock Now Up 31.51%

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Buy and maintains $6 price target.

LXRX

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

A widely watched gauge of bond market volatility has surged to its highest level in over a year as American voters cast their ballots in one of the closest presidential <a href="https://www.benzinga.com/topic/2024-election">races in recent history. </a>
The ICE BofAML U.S. Bond Market Option Volatility Estimate Index, or &#8220;MOVE&#8221; index, closed at 136 on Monday, reaching levels last seen in early October 2023. 
This spike in the MOVE index highlights mounting anxiety in the bond market, driven by political uncertainty and fears of inflationary fiscal policies.
<h3 class="wp-block-heading">What Is The MOVE Index?</h3>
The MOVE index, often described as the VIX for bonds, measures expected volatility in the Treasury market based on options pricing. 
Like the VIX, which tracks volatility in the equity market, the MOVE index is seen as a &#8220;fear gauge&#8221; for fixed-income investors. 
Higher MOVE readings indicate increased uncertainty about future bond price movements, reflecting traders&#8217; fears around interest rates, inflation, and broader economic conditions.
See Also: <a href="https://www.benzinga.com/money/guide-to-volatility-indices-vix">Beginners Guide to VIX or Volatility Indices</a>
<h3 class="wp-block-heading">Election Jitters Fuel Bond Market Anxiety</h3>
The U.S. presidential election has investors on edge, with polls showing one of the tightest races in modern American history. 
Neither Vice President Kamala Harris nor ex-President Donald Trump held a meaningful lead in critical battleground states ahead of Nov. 5, <a href="https://www.nytimes.com/interactive/2024/us/elections/polls-president.html">wrote</a> Nate Cohn, chief political analyst at the New York Times. 
&#8220;In the history of modern polling, there's never been a campaign where the final polls showed such a close contest,&#8221; he added.
The possibility of a prolonged, contentious result has amplified concerns in the bond market, where volatility has jumped 51% since late September. 
Fixed-income investors are also weighing the potential fiscal impact of each candidate&#8217;s policies, especially if the winner's administration fuels inflation and adds to the federal debt.
According to the Committee for a Responsible Federal Budget (CRFB), Trump's spending plans could increase the national debt by $7.75 trillion over the next decade, driving the debt-to-GDP ratio to 143% by 2035. By contrast, Kamala Harris's proposals would add $3.95 trillion to the debt, resulting in a debt-to-GDP ratio of approximately 134% by the same year.
Chart: Bond Volatility Index Has Risen By Over 50% Since Late-September
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-1024x501.png" alt="" class="wp-image-630321" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05084449/image-31.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Trump's Tariff Plans Stoke Inflation Fears</h3>
Under a Trump administration, inflation could rise if proposed tariffs on Chinese imports and other goods come into effect. 
Trump has floated a 60% tariff on Chinese products and a universal 10% tariff, policies which JPMorgan analysts estimate could drive inflation up by as much as 2.4% in a worst-case scenario. 
&#8220;Tariffs are inflationary,&#8221; IMF deputy managing director Gita Gopinath warned in October.
With inflation a growing concern, Treasury yields have been on an upward trajectory, as investors demand higher returns to offset potential future price increases. 
Yields on the 10-year Treasury bond have risen by 50 basis points last month and hit 4.33% on Tuesday. 
<h3 class="wp-block-heading">&#8216;Bond Vigilantes&#8217; Are Back</h3>
The bond market&#8217;s reaction to these uncertainties has been swift and severe. 
&#8220;Nothing seems to be stopping U.S. Treasury bond yields from rising,&#8221; said veteran Wall Street investor Ed Yardeni. 
&#8220;The Bond&nbsp;Vigilantes&nbsp;have been voting early (and voting often) by selling US Treasury notes and bonds,&#8221; he added. 
The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>), which tracks long-dated Treasuries, fell nearly 6% in October 2024.
With both candidates likely to enact substantial stimulus, Yardeni stated, &#8220;The bond market is tightening the economy itself,&#8221; as investors anticipate inflation and higher interest rates. 
Yardeni indicated this surge in yields could push the 10-year Treasury into the 5% range, a level not seen since before the financial crisis.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a></li>
</ul>
Image: Shutterstock

Analyst Color

Macro Economic Events

Bonds

Specialty ETFs

Politics

Treasuries

Econ #s

Economics

ETFs

iShares Trust Barclays 20+ Year Treasury Bond Fund

Bond Market Fear Gauge Soars To 1-Year High Ahead Of US Election Results: 'Bond Vigilantes Have Been Voting Early'

Deutsche Bank analyst Benjamin Soff maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and raises the price target from $122 to $130.

Deutsche Bank Maintains Buy on Live Nation Entertainment, Raises Price Target to $130

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid the US presidential election.

<a href="https://x.com/WolfpackReports/status/1853809784731873633" title="https://x.com/WolfpackReports/status/1853809784731873633">https://x.com/WolfpackReports/status/1853809784731873633</a>

Shares Of MediaAlpha See Volume; Wolfpack Research Thread On X, "We warned everyone about $MAX and the FTC investigation…"

Market Summary

PLTR

Benzinga Market Summary: Global Markets On Watch Amid US Presidential Election, Gold And Oil Move Higher, Palantir Surges On Strong Guidance

Investors with a lot of money to spend have taken a bullish stance on Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with META, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 31 uncommon options trades for Meta Platforms.
This isn't normal.
The overall sentiment of these big-money traders is split between 38% bullish and 35%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $641,951, and 26 are calls, for a total amount of $1,896,313.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $400.0 to $820.0 for Meta Platforms over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Meta Platforms stands at 2470.58, with a total volume reaching 12,875.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Meta Platforms, situated within the strike price corridor from $400.0 to $820.0, throughout the last 30 days.
<h3>Meta Platforms Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817964_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$11.8</td>
<td>$11.6</td>
<td>$11.68</td>
<td>$540.00</td>
<td>$274.7K</td>
<td>5.6K</td>
<td style="text-align: right;">419</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$11.65</td>
<td>$11.45</td>
<td>$11.56</td>
<td>$610.00</td>
<td>$271.9K</td>
<td>2.3K</td>
<td style="text-align: right;">438</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$82.15</td>
<td>$81.6</td>
<td>$82.15</td>
<td>$500.00</td>
<td>$164.3K</td>
<td>12.0K</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$83.35</td>
<td>$82.15</td>
<td>$82.1</td>
<td>$500.00</td>
<td>$164.2K</td>
<td>12.0K</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$253.4</td>
<td>$252.2</td>
<td>$253.4</td>
<td>$820.00</td>
<td>$152.0K</td>
<td>11</td>
<td style="text-align: right;">6</td>
</tr>
</tbody>
</table>

<h3>About Meta Platforms</h3>
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
In light of the recent options history for Meta Platforms, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Meta Platforms Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,457,256, with META's price down by -1.21%, positioned at $560.29.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 86 days.</li>
</ul>
<h3>Professional Analyst Ratings for Meta Platforms</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $665.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Meta Platforms, targeting a price of $650. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Meta Platforms, targeting a price of $650. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Meta Platforms, targeting a price of $650. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $670. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Meta Platforms, maintaining a target price of $705. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Meta Platforms options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Looking At Meta Platforms's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BKNG, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Booking Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 77% bullish and 0%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $53,435, and 7 are calls, for a total amount of $528,728.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3600.0 and $5750.0 for Booking Holdings, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Booking Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Booking Holdings's whale activity within a strike price range from $3600.0 to $5750.0 in the last 30 days. 
<h3>Booking Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817959_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1248.0</td>
<td>$1232.0</td>
<td>$1248.0</td>
<td>$3600.00</td>
<td>$124.8K</td>
<td style="text-align: right;">337</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1227.7</td>
<td>$1205.5</td>
<td>$1218.0</td>
<td>$3600.00</td>
<td>$121.8K</td>
<td style="text-align: right;">24</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$467.6</td>
<td>$442.6</td>
<td>$459.59</td>
<td>$4410.00</td>
<td>$91.9K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$818.9</td>
<td>$800.0</td>
<td>$818.9</td>
<td>$4150.00</td>
<td>$81.8K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$492.8</td>
<td>$488.6</td>
<td>$492.8</td>
<td>$4600.00</td>
<td>$49.2K</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>

<h3>About Booking Holdings</h3>
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
After a thorough review of the options trading surrounding Booking Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Booking Holdings Standing Right Now?</h3>
<ul>
<li>With a trading volume of 3,661, the price of BKNG is down by -0.14%, reaching $4770.0.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 107 days from now.</li>
</ul>
<h3>What The Experts Say On Booking Holdings</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $4852.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Booking Holdings, which currently sits at a price target of $4510. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Booking Holdings with a target price of $4600. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Booking Holdings with a target price of $5250. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Booking Holdings, which currently sits at a price target of $5000. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Booking Holdings with a target price of $4900. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Booking Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

BKNG

A Closer Look at Booking Holdings's Options Market Dynamics

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!



Moving stocks this morning are earnings reports, acquisition plans, new drug data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>INVO Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is rocketing more than 55% alongside its <a href="https://finance.yahoo.com/news/invo-reports-fourth-quarter-full-205900118.html">Q4 earnings report</a>.</li>



<li>Vanda Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/">VNDA</a>) shares are soaring over 38% on <a href="https://www.nasdaq.com/press-release/future-pak-confirms-proposal-to-acquire-vanda-pharmaceuticals-for-%247.25-to-%247.75-per">a firm acquisition proposal</a>.</li>



<li>VIA Optronics (NYSE:<a href="https://investorplace.com/stock-quotes/viao-stock-quote/">VIAO</a>) stock is surging more than 32% with heavy pre-market trading.</li>



<li>Clene (NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/">CLNN</a>) shares are rising over 26% on <a href="https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain%7Csection%3Aon-the-move">new drug data</a>.</li>



<li>Chromocell Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/">CHRO</a>) stock is gaining more than 26% on an update to a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239123&amp;type=PDF&amp;symbol=CHRO&amp;cdn=722216dc7f57070dff83767fe9648f9d&amp;companyName=Chromocell+Therapeutics+Corporation&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-04-17">secondary stock offering</a>.</li>



<li>CXApp (NASDAQ:<a href="https://investorplace.com/stock-quotes/cxai-stock-quote/">CXAI</a>) shares are increasing over 26% with its <a href="https://www.marketwatch.com/story/cxapp-shares-rise-29-on-4q-2023-annual-recurring-revenue-growth-13f8abea">latest earnings report</a>.</li>



<li>Seelos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/">SEEL</a>) stock is climbing more than 24% without any clear news on Wednesday morning.</li>



<li>Mobile Global Esports (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgam-stock-quote/">MGAM</a>) shares are getting a 22% boost as it <a href="https://investorplace.com/2024/04/why-is-mobile-global-esports-mgam-stock-down-18-today/">prepares for delisting</a>.</li>



<li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is jumping 21% despite a lack of news today.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are up over 19% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238318&amp;type=PDF&amp;symbol=GRTX&amp;cdn=6788b7c94daccbdc9a6c5412e270d44c&amp;companyName=Galera+Therapeutics+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-16">shareholder stake update</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Trilogy Metals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tmq-stock-quote/">TMQ</a>) stock is plummeting more than 22% <a href="https://www.nasdaq.com/press-release/trilogy-metals-provides-update-on-the-ambler-access-project-2024-04-17">following an update</a> to its Ambler Access Project.</li>



<li>Trio Petroleum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/">TPET</a>) shares are diving over 20% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239194&amp;type=PDF&amp;symbol=TPET&amp;cdn=fb7a5495a316777660288b1087458323&amp;companyName=Trio+Petroleum+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-17">securing senior notes and a purchase agreement</a>.</li>



<li>Connexa Sports Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/">YYAI</a>) stock is tumbling more than 18% on Wednesday morning.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are taking a close to 18% beating following a rally yesterday.</li>



<li>Ontrak (NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/">OTRK</a>) stock is sliding over 16% with the release of its <a href="https://finance.yahoo.com/news/ontrak-announces-2023-fourth-quarter-200500612.html">Q4 2023 earnings report</a>.</li>



<li>Dragonfly Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/">DFLI</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/04/why-is-dragonfly-energy-dfli-stock-up-56-today/">after rallying yesterday</a>.</li>



<li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) stock is pulling back over 16% <a href="https://investorplace.com/2024/04/why-is-dynatronics-dynt-stock-up-93-today/">after rising on Tuesday</a>.</li>



<li>Ryvyl (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/">RVYL</a>) shares are still falling more than 15% despite <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-cancellation-of-proposed-underwritten-public-offering-2024-04-16">canceling a proposed public offering</a>.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is dropping over 14% <a href="https://investorplace.com/2024/04/why-is-hub-cyber-security-hubc-stock-up-35-today/">after a rally yesterday</a>.</li>



<li>iSun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) shares close out our pre-market stock movers down more than 13% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238741&amp;type=PDF&amp;symbol=ISUN&amp;cdn=82f25393dbc89b776256155c3f0856b7&amp;companyName=iSun+Inc.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-16">on an investor update</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

SBFM, BPTH and INDO among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chromocell Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/">CHRO</a>) just reported results for the first quarter of 2024.<ul><li>Chromocell Therapeutics reported earnings per share of -55 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/chro-stock-earnings-chromocell-therapeutics-for-q1-of-2024/">CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024

Chromocell Therapeutics Corp (CHRO) has provided an update. Chromocell Therapeutics Corporation has recently entered into financial agreements that...

Chromocell Therapeutics Strengthens Finances with Strategic Agreements

Chromocell announces stock repurchase plan

Wall Street Breakfast: The Week Ahead

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chromocell Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/">CHRO</a>) just reported results for the second quarter of 2024.<ul><li>Chromocell Therapeutics reported earnings per share of -31 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/chro-stock-earnings-chromocell-therapeutics-for-q2-of-2024/">CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024

Chromocell Therapeutics (CHRO) board of directors has authorized an amendment to the Company's existing stock repurchase plan to increase the total...

Chromocell Therapeutics announces amendment to stock repurchase plan

Chromocell announces amendment to stock repurchase plan

Chromocell Therapeutics (CHRO) announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-...

Chromocell unveils injectable depot program for treating surgical pain

AMAT

ARDT

ARTV

BABA

BDTX

CHRO

CLNN

CSCO

CXAI

DFLI

DXYZ

DYNT

EDBL

GOLD

GPAK

GRTX

GTHX

HEPA

HUBC

INVO

ISUN

IVCA

MDIA

MGAM

MNDR

MNDY

NVFY

ONON

OTRK

PAAS

PINS

RVYL

RWOD

SAVA

SAVE

SEEL

SNAP

SPGC

TPET

TWFG

VIAO

VNDA

VZLA

YYAI

ZCMD

Interview

This Biotech Is Innovating In Non-Opiod Solutions For Intense Pain

Health Care

Press Releases

Chromocell  Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024

Chromocell to Participate in the Virtual Investor Lunch Break Series

Financing

Chromocell Announces Stock Repurchase Plan

Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Chromocell to Participate in Life Sciences Investor Forum September 19th

Chromocell Announces Amendment to Stock Repurchase Plan

Chromocell to Present at Upcoming Fall Investor Conferences

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

Comments

Chromocell Therapeutics

Notizie

Ultime notizie per Chromocell Therapeutics (AMEX:CHRO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO